(3aR,5aR,9bS)-3a-hydroxy-5a,9-dimethyl-3-(piperidin-1-ylmethyl)-3,3a,4,5,5a,6,7,8-octahydronaphtho[1,2-b]furan-2(9bH)-one | 113762-78-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (3aR,5aR,9bS)-3a-hydroxy-5a,9-dimethyl-3-(piperidin-1-ylmethyl)-3,3a,4,5,5a,6,7,8-octahydronaphtho[1,2-b]furan-2(9bH)-one
• 英文别名: (3aR,5aR,9bS)-3,3a,4,5,5a,6,7,8,-octahydro-3a-hydroxy-5a,9-dimethyl-3-((piperidin-1-yl)methyl)naphtho[1,2-b]furan-2(9bH)-one；(3aR,5aR,9bS)-3a-hydroxy-5a,9-dimethyl-3-(piperidin-1-ylmethyl)-4,5,6,7,8,9b-hexahydro-3H-benzo[g][1]benzofuran-2-one
• CAS: 113762-78-0
• 化学式: C₂₀H₃₁NO₃
• 分子量: 333.471
• InChiKey: RKPNEEXUCKXFQO-RWWRMHFQSA-N

物化性质

• 沸点：
  493.3±45.0 °C(predicted)
• 密度：
  1.17±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  7-hydroxyfrullanolide 、 哌啶 以 四氢呋喃 为溶剂， 反应 1.5h， 以44%的产率得到(3aR,5aR,9bS)-3a-hydroxy-5a,9-dimethyl-3-(piperidin-1-ylmethyl)-3,3a,4,5,5a,6,7,8-octahydronaphtho[1,2-b]furan-2(9bH)-one
  参考文献：
  名称：

  [EN] 7-HYDROXYFRULLANOLIDE AND ITS ANALOGS FOR PREVENTION, CONTROL AND TREATMENT OF METABOLIC DISORDERS
  [FR] 7-HYDROXYFRULLANOLIDE ET SES ANALOGUES POUR LA PRÉVENTION, LA MAÎTRISE ET LE TRAITEMENT DE TROUBLES DU MÉTABOLISME.

  摘要：

  本发明揭示了从7- 羟基富尔醛内酯、其类似物、提取物和分离物中选择的生物活性成分，这些成分经标准化处理得到7- 羟基富尔醛内酯或其类似物或两者或二者的混合物，或它们的组合物，用于预防、控制和治疗一种或多种肥胖、超重、代谢综合征、糖尿病和其他代谢紊乱，或用于在需要的温血动物中产生瘦体重。

  公开号：

  WO2012014216A1

文献信息

• [EN] TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS TRICYCLIQUES POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2009016565A1

  公开（公告）日：2009-02-05

  The present invention provides compounds represented by general formula (1) wherein, R1 R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined in the specification, in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. These compounds are useful for treatment of inflammatory disorders including those caused by elevated levels of proinflammatory cytokines such as Tumor Necrosis Factor (TNF-α and/or interleukins (IL-1β, IL-6, IL-8). The invention also relates to processes for the manufacture of compounds of formula (1) and pharmaceutical compositions containing them.

  本发明提供了由通式（1）表示的化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13和X如规范中定义的那样，在所有立体异构体和互变异构体形式以及它们的混合物中的所有比例中，以及其药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的多型体和前药。这些化合物对于治疗包括由促炎细胞因子水平升高引起的炎症性疾病很有用，如肿瘤坏死因子（TNF-α）和/或白细胞介素（IL-1β、IL-6、IL-8）。该发明还涉及制备通式（1）化合物的方法以及含有它们的制药组合物。
• SOHONI, JAYANT S.;ROJATKAR, SUPADA R.;KULKARNI, MANDAKINI M.;DHANESHWAR, +, J. CHEM. SOC. PERKIN TRANS.,(1988) N 2, 157-160
  作者：SOHONI, JAYANT S.、ROJATKAR, SUPADA R.、KULKARNI, MANDAKINI M.、DHANESHWAR, +

  DOI：——

  日期：——
• Sohoni, Jayant S.; Rojatkar, Supada R.; Kulkarni, Mandakini M., Journal of the Chemical Society. Perkin transactions I, 1988, p. 157 - 160
  作者：Sohoni, Jayant S.、Rojatkar, Supada R.、Kulkarni, Mandakini M.、Dhaneshwar, Narayandatta N.、Tavale, Sudam S.、et al.

  DOI：——

  日期：——
• 7-HYRDROXYFRULLANOLIDE ITS ANALOGS FOR PREVENTION CONTROL AND TREATMENT OF METABOLIC DISORDERS
  申请人：LAILA NUTRACEUTICALS

  公开号：US20130136809A1

  公开（公告）日：2013-05-30

  The invention discloses biologically active ingredient(s) selected from 7-hydroxyfrullanolide, its analogs, the ex-tract(s) and fraction(s) standardized to 7-hydroxyfrullanolide or its analogs or both or mixtures thereof or their composition(s) for the prevention, control and treatment of one or more obesity, overweight, metabolic syndrome, diabetes and other metabolic disorders or for producing lean body mass in a warm blooded animal in need thereof.